Berkeley Lights, Bayer Ink Discovery Pact For Next-Gen Traits In Agricultural Sector, Berkeley Q2 Earnings Miss Estimates

Berkeley Lights Inc BLI reports Q2 sales of $19.3 million, +82% Y/Y, but slightly missing the consensus of $19.64 million.
The Company expanded the installed base to 92 platforms, with seven new direct placements shipped in the quarter. The gross margin remains unchanged at 66%.
It reported a wider operating loss of $(17.8) million, compared to $(12.2) million a year ago.
Net loss swelled to $(18.1) million, compared to $(12.4) million in Q2 FY20.
EPS loss of $(0.27) versus $(4.25) a year ago, missed the consensus of $(0.24).
Berkeley Lights continues to expect full-year 2021 revenue of $90 million - $100 million, a Y/Y growth of 40% - 56%.
Separately, Berkeley has announced a multi-year agreement with Bayer AG BAYRY to develop and perform high-throughput functional screening workflows to accelerate and expand the discovery of novel traits.
The terms of the agreement were not disclosed.
Berkeley Lights will leverage its platform to screen individual bioactive variants for Bayer, marking the first application of Berkeley Lights' technology for use in the agricultural sector.
Price Action: BLI shares are down 4.09% at $42 premarket on the last check Wednesday.

Earnings Calendar